Profile-QSAR and Surrogate AutoShim Protein-Family Modeling of Proteases
暂无分享,去创建一个
[1] D. Fairlie,et al. Protease inhibitors in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).
[2] J. Powers,et al. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases , 2003 .
[3] L. Hedstrom. Serine protease mechanism and specificity. , 2002, Chemical reviews.
[4] Eric J. Martin,et al. Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..
[5] H. Katus,et al. New antithrombotic drugs on the horizon , 2003, Expert opinion on investigational drugs.
[6] B. Turk. Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.
[7] N. Rawlings,et al. Evolutionary families of peptidases. , 1993, The Biochemical journal.
[8] N. Rosen,et al. Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.
[9] Eric J. Martin,et al. Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure , 2008, J. Chem. Inf. Model..
[10] Ingemar Nilsson,et al. A new oral anticoagulant: the 50-year challenge , 2004, Nature Reviews Drug Discovery.
[11] James F. Riordan,et al. Ace revisited: A new target for structure-based drug design , 2003, Nature Reviews Drug Discovery.
[12] Erik De Clercq,et al. Antiviral drugs in current clinical use. , 2004 .
[13] G. Salvesen,et al. Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.
[14] D. C. Sullivan,et al. AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data. , 2008 .
[15] Jeffrey Jie-Lou Liao,et al. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors , 2007 .
[16] Eric J. Martin,et al. AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data , 2008, J. Chem. Inf. Model..
[17] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[18] Carlos López-Otín,et al. Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.
[19] X. Puente,et al. Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.
[20] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[21] A. Ribas,et al. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.
[22] Jun Kong,et al. MEROPS: the peptidase database. , 2004, Nucleic acids research.
[23] G. Bemis,et al. Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.